RTTNews) - Gilead Sciences Inc. (GILD) announced that phase 1 study data showed two different formulations of once-yearly lenacapavir, administered via intramuscular injection, achieved and maintained plasma concentrations exceeding those associated with HIV prevention efficacy...
4990 Ash Street, Dallas, Texas 75207 972-815-7120
972-815-7120
admin@finhub.com
Copyright © 2024 finance. All Rights Reserved